Evidence method
Level · gp.fundamentals.debt_to_revenue
45.45% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Sep 30, 2018
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-18-000038General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.14% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
20.48% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
-0.23% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
8.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
47.90% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
31.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
14.08% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.34% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.23% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 43.89%
- Current
- 45.45%
- Delta
- 1.56%
- Previous
- 4.51%
- Current
- 6.14%
- Delta
- 1.62%
- Previous
- 18.32%
- Current
- 20.48%
- Delta
- 2.15%
- Previous
- -0.63%
- Current
- -0.23%
- Delta
- 0.39%
- Previous
- 12.55%
- Current
- 8.41%
- Delta
- -4.14%
- Previous
- 46.53%
- Current
- 47.90%
- Delta
- 1.38%
- Previous
- 31.78%
- Current
- 31.41%
- Delta
- -0.37%
- Previous
- 13.47%
- Current
- 14.08%
- Delta
- 0.61%
- Previous
- 2.41%
- Current
- 2.34%
- Delta
- -0.07%
- Previous
- 1.34%
- Current
- 1.23%
- Delta
- -0.11%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST GROWTH_DECREASED →Transitioned To · WST INVENTORY_PRESSURE_INCREASED →Transitioned To · WST MARGIN_DECREASED →Transitioned To · WST PROFITABILITY_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →Transitioned To · WST SBC_INTENSITY_DECREASED →Transitioned To · WST BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · WST CAPEX_INTENSITY_INCREASED →Transitioned To · WST CASH_GENERATION_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.